Provided herein are edible compositions for reducing semen viscosity and/or enhancing semen flavor, and methods of using and preparing such compositions.

Described are compositions, in particular lyophilizates, containing proteolytic enzymes, and methods for producing the compositions. Typically these compositions contain one or more proteases with collagenase activity and a neutral protease, for example, thermolysin. The compositions are free of acetate salts. Surprisingly, such compositions can be dissolved in water more rapidly than lyophilized protease mixtures of the state of the art.

The invention relates to compositions and methods for treating uterine fibroids, wherein a uterine fibroid treatment agent comprising collagenase in an amount effective to cause shrinkage of uterine fibroids is injected or inserted into the uterine fibroid.

A method for culturing placental potential cell is provided, comprising steps of: (1) obtaining placental cells and/or tissue under aseptic condition; (2) inoculating the placental cells and/or the tissue in a culture medium for culturing, adding cell growth regulators to the culture medium, in such a manner that the placental potential cells grows to make the placental cells and/or the tissue into a proliferative state; (3) culturing the placental potential cells to make the placental potential cells proliferate continuously into cells with characteristics of stem cells. The present invention not only finds the source of human tissues, organs and the continuation of their function, i.e., regenerative potential cells; but also finds a medical and health longevity method, but also finds out the life materials to maintain and support the potential cells, so as to replace drugs with the living material.

The present invention claims a novel process for the production and purification of microbial collagenase (Microbial Collagenase EC 3.4.24.3) produced by the non-pathogenic aerobic bacterium Vibrio alginolyticus chemovar. iophagus (NCIMB Number: 1 1038, synonym LMG 3418, hereinafter called Vibrio alginolyticus), which said process provides high production levels of collagenase with a stable, reproducible, cheap fermentation process. The collagenase produced from Vibrio alginolyticus according to the process described herein also presents a specific activity superior to that of other microbial collagenases, is stable in aqueous solution, and can be frozen without significant damage. A further subject of the present invention is pharmaceutical compositions containing collagenase obtained according to the production and purification process described, for the purpose of therapeutic treatment of disorders characterized by collagen accumulation or for the treatment of blemishes/imperfections that benefit from reducing local collagen accumulations.

Disclosed herein are improved collagenase-containing formulations and methods of preparing the same. The collagenase-containing formulations comprise a collagenase, about 30 mM to about 240 mM of a disaccharide, about 50 mM to about 800 mM of mannitol, and about 6 mM to about 10 mM of a Tris-HCl. Lyophilized and reconstituted formulations are also provided.

The present invention refers to a culture medium and a process for producing Clostridium collagenolytic and gelatinolytic proteases. The present invention includes an animal product-free culture medium for C. histolyticum comprising non-animal derived peptones, preferably vegetable derived peptones, yeast extract and the amino acids cysteine and arginine. The present invention also includes a process for producing a supernatant of Clostridium histolyticum liquid culture comprising one or more collagenolytic and gelatinolytic proteases, and pharmaceutical composition comprising as active ingredient a supernatant of the Clostridium cultures described herein.

The present invention relates to pharmaceutical formulations comprising xanthine or xanthine derivatives, kits thereof, and methods for treating fibrotic diseases by local administration.

Provided are purification methods and uses of a recombinant mutant collagenase, and methods for preparing high-purity mutant ColH and the purified enzyme product. The method for preparing high-purity mutant ColH includes expressing recombinant mutant collagenase protein with single mutation of E451D in ColH by using specific host strain E. coli BL21 (DE3), and improving yield of the target protein after induction by low-temperature fermentation. The purification includes five steps: Capto Phenyl HS hydrophobic interaction chromatography; Capto Q anion exchange chromatography; Capto Octyl hydrophobic interaction chromatography; Phenyl HP hydrophobic interaction chromatography and Source 15Q anion exchange chromatography. The target protein obtained has purity of over 98%.

The present disclosure relates to a method for rating the severity of cellulite on a thigh or buttock in a human subject by utilizing a photonumeric scale that provides reliable results from physician-to-physician and patient-to-patient.